# CALGB 10403 (NCT00558519)

> Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00558519
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Alliance for Clinical Trials in Oncology
- Conditions: Leukemia
- Interventions: cyclophosphamide; cytarabine; daunorubicin hydrochloride; dexamethasone; doxorubicin hydrochloride; mercaptopurine; methotrexate; pegaspargase; thioguanine; vincristine sulfate; radiation therapy
- Enrollment: 318
- Primary outcome: Complete Response Rate
- Primary outcome: Event-free Survival
- Primary outcome: Disease-free Survival
- Primary outcome: Overall Survival
- Primary outcome: Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)

## Indexed commentary on CALGB 10403 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 115
- YouTube: 19
- Podcasts: 12
- Bluesky threads: 11

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=calgb-10403-nct00558519

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00558519", "email": "<work email>"}; the inbox owner confirms by the emailed link.